Clinical and economic studies of eptifibatide in coronary stenting

References

• NordmannAJHengstlerPLeimenstollBMHarrTYoungJBucherHCClinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: a meta-analysis of randomized controlled trialsEur Heart J2004251698014683745
   PubMed Web of Science ®Google Scholar
• van WerkumJWHeestermansAAZomerACPredictors of coronary stent thrombosis: the Dutch Stent Thrombosis RegistryJ Am Coll Cardiol200953161399140919371823
   PubMed Web of Science ®Google Scholar
• GurbelPACummingsCCBellCRAlfordABMeisterAFSerebruanyVLOnset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trialAm Heart J2003145223924712595840
   PubMed Web of Science ®Google Scholar
• SteinhublSREllisSGWolskiKLincoffAMTopolEJTiclopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) TrialCirculation2001103101403140911245644
   PubMed Web of Science ®Google Scholar
• CutlipDEBaimDSHoKKLStent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trialsCirculation2001103151967197111306525
   PubMed Web of Science ®Google Scholar
• HolmesDRJrKereiakesDJGargSStent thrombosisJ Am Coll Cardiol201056171357136520946992
   PubMed Web of Science ®Google Scholar
• ReynoldsMRRinaldiMJPintoDSCohenDJCurrent clinical characteristics and economic impact of subacute stent thrombosisJ Invasive Cardiol200214736436812082187
   PubMedGoogle Scholar
• ClarkMABakhaiALaceyMJPelletierEMCohenDJClinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims dataCirculation2004110325926415226211
   PubMed Web of Science ®Google Scholar
• McKeeSASaneDCDeliargyrisENAspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significanceThromb Haemost200288571171512428082
   PubMed Web of Science ®Google Scholar
• StarnesHBPatelAAStoufferGAOptimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventionsDrugs201171152009203021985168
   PubMed Web of Science ®Google Scholar
• KristensenSDWurtzMGroveELContemporary use of glycoprotein IIb/IIIa inhibitorsThromb Haemost2012107221522422234385
   PubMed Web of Science ®Google Scholar
• ScarboroughRMNaughtonMATengWDesign of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIaJ Biol Chem19932682106610738419315
   PubMed Web of Science ®Google Scholar
• TamSHSassoliPMJordanRENakadaMTAbciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrinsCirculation19989811108510919736595
   PubMed Web of Science ®Google Scholar
• KereiakesDJRunyonJPBroderickTMShimshakTMIIb’s are not IIb’sAm J Cardiol2000858A23C31C
   PubMed Web of Science ®Google Scholar
• HarringtonRAKleimanNSKottke-MarchantKImmediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionAm J Cardiol19957617122212277503000
   PubMed Web of Science ®Google Scholar
• [No authors listed]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-IILancet19973499063142214289164315
   PubMed Web of Science ®Google Scholar
• MarciniakSJJrJordanREMascelliMAEffect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofibanThromb Haemost200185353954311307828
   PubMed Web of Science ®Google Scholar
• KereiakesDJLorenzTYoungJJDifferential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofibanJ Thromb Thrombolysis200112212312711729363
   PubMed Web of Science ®Google Scholar
• TchengJETalleyJDO’SheaJCClinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)Am J Cardiol200188101097110211703951
   PubMed Web of Science ®Google Scholar
• ZeymerUZahnRSchieleREarly eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trialEur Heart J200526191971197715857851
   PubMed Web of Science ®Google Scholar
• GibsonCMKirtaneAJMurphySAEarly initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trialAm Heart J2006152466867516996831
   PubMed Web of Science ®Google Scholar
• Le MayMRWellsGAGloverCAPrimary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST)Circ Cardiovasc Interv20092433033820031736
   PubMed Web of Science ®Google Scholar
• StoneGWWitzenbichlerBGuagliumiGBivalirudin during primary PCI in acute myocardial infarctionN Engl J Med2008358212218223018499566
   PubMed Web of Science ®Google Scholar
• MehranRLanskyAJWitzenbichlerBBivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trialLancet200937496961149115919717185
   PubMed Web of Science ®Google Scholar
• [No authors listed]Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin TherapyN Engl J Med199833974364439705684
   PubMed Web of Science ®Google Scholar
• KleimanNSLincoffAMFlakerGCEarly percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromesCirculation2000101775175710683348
   PubMed Web of Science ®Google Scholar
• [No authors listed]Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialLancet200035692472037204411145489
   PubMed Web of Science ®Google Scholar
• PumaJABankoLTPieperKSClinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trialJ Am Coll Cardiol200647471571816487833
   PubMed Web of Science ®Google Scholar
• StoneGWWhiteHDOhmanEMBivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trialLancet2007369956590791917368152
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJAHarringtonRABivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialJAMA2003289785386312588269
   PubMed Web of Science ®Google Scholar
• GibsonCMMorrowDAMurphySAA randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trialJ Am Coll Cardiol200647122364237316781360
   PubMed Web of Science ®Google Scholar
• ZeymerUMargenetAHaudeMRandomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI TrialJ Am Coll Cardiol201056646346920670755
   PubMed Web of Science ®Google Scholar
• AkerblomAJamesSKKoutouzisMEptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)J Am Coll Cardiol201056647047520670756
   PubMed Web of Science ®Google Scholar
• SinghHSDangasGDGuagliumiGComparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial)Am J Cardiol2012110794094722748356
   PubMed Web of Science ®Google Scholar
• LopesRDAlexanderKPManoukianSVAdvanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialJ Am Coll Cardiol200953121021103019298914
   PubMed Web of Science ®Google Scholar
• AlexanderKPChenAYNewbyLKSex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) initiativeCirculation2006114131380138716982940
   PubMed Web of Science ®Google Scholar
• AlexanderKPChenAYRoeMTExcess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromesJAMA2005294243108311616380591
   PubMed Web of Science ®Google Scholar
• FungAYSawJStarovoytovAAbbreviated infusion of eptifibatide after successful coronary intervention the BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trialJ Am Coll Cardiol2009531083784519264239
   PubMed Web of Science ®Google Scholar
• KiniASChenVHKrishnanPBolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventionAm Heart J2008156351351918760134
   PubMed Web of Science ®Google Scholar
• DalbyMMontalescotGBal dit SollierCEptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) studyJ Am Coll Cardiol200443216216814736431
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPZamanKAYohoJAHayesKMTantryUSClopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) studyCirculation200511191153115915738352
   PubMed Web of Science ®Google Scholar
• GiuglianoRPWhiteJABodeCEarly versus delayed, provisional eptifibatide in acute coronary syndromesN Engl J Med2009360212176219019332455
   PubMed Web of Science ®Google Scholar
• StoneGWBertrandMEMosesJWRoutine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trialJAMA2007297659160217299194
   PubMed Web of Science ®Google Scholar
• HamonMRasmussenLHManoukianSVChoice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trialEuroIntervention20095111512019577992
   PubMed Web of Science ®Google Scholar
• MoodyWEChueCDLudmanPFBleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trialCatheter Cardiovasc Interv2013823E138E14723074143
   PubMed Web of Science ®Google Scholar
• EichhoferJHorlickEIvanovJDecreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experienceAm Heart J2008156586487019061699
   PubMed Web of Science ®Google Scholar
• MarkDBHarringtonRALincoffAMCost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromesCirculation2000101436637110653826
   PubMed Web of Science ®Google Scholar
• PloskerGLIbbotsonTEptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromesPharmacoeconomics2003211288591212908844
   PubMed Web of Science ®Google Scholar
• DewildeSBruggenjurgenBNienaberCSengesJWelteRWillichSNCost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in GermanyEur J Health Econ201213438139121484498
   PubMed Web of Science ®Google Scholar
• PRICE InvestigatorsComparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) TrialAm Heart J2001141340240911231437
   PubMed Web of Science ®Google Scholar
• CoonsJCSeybertALSaulMIKirisciLKane-GillSLOutcomes and costs of abciximab versus eptifibatide for percutaneous coronary interventionAnn Pharmacother200539101621162616105872
   PubMed Web of Science ®Google Scholar
• Le PenCLilliuHChoice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?Pharm World Sci2005272839115999917
   PubMedGoogle Scholar
• CantorWJFitchettDBorgundvaagBRoutine early angioplasty after fibrinolysis for acute myocardial infarctionN Engl J Med2009360262705271819553646
   PubMed Web of Science ®Google Scholar
• BagaiACantorWJTanMClinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) studyAm Heart J20131654630637. e63223537982
   PubMed Web of Science ®Google Scholar
• CohenDJLincoffAMLavelleTAEconomic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trialJ Am Coll Cardiol20044491792180015519009
   PubMed Web of Science ®Google Scholar
• SummersKMHoldfordDACrouchMACost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary interventionPharmacotherapy200626560961816637790
   PubMed Web of Science ®Google Scholar
• PintoDSStoneGWShiCEconomic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromesJ Am Coll Cardiol200852221758176819022155
   PubMed Web of Science ®Google Scholar
• AminAPMagnusonEAUnderstanding the cost-effectiveness of bivalirudinHeart201298141037103922739634
   PubMed Web of Science ®Google Scholar
• SchwenkglenksMTowardTJPlentSSzucsTDBlackmanDJBaumbachACost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarctionHeart201298754455122313548
   PubMed Web of Science ®Google Scholar
• FischellTAAttiaTRaneSSalmanWHigh-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventionsJ Invasive Cardiol2006181048749117042093
   PubMedGoogle Scholar
• HelmyTEffatMCommentary: alternative safe, effective and cost-efficient dosing for eptifibatide in low-risk patientsJ Invasive Cardiol2006181049249317042095
   PubMedGoogle Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• O’GaraPTKushnerFGAscheimDD2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol2013614e78e14023256914
   PubMed Web of Science ®Google Scholar
• WrightRSAndersonJLAdamsCD2011 ACCF/AHA focused update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol201157191920195921450428
   PubMed Web of Science ®Google Scholar
• LevineGNBatesERBlankenshipJC2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventionsCirculation20121258e412
   Google Scholar
• CuissetTFrereCQuiliciJGlycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders. a prospective, randomized studyJACC Cardiovasc Interv20081664965319463379
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• BhattDLLincoffAMGibsonCMIntravenous platelet blockade with cangrelor during PCIN Engl J Med2009361242330234119915222
   PubMed Web of Science ®Google Scholar